Reuters logo
Basilea shares fall after setback for pneumonia treatment in US
June 25, 2014 / 7:26 AM / in 3 years

Basilea shares fall after setback for pneumonia treatment in US

ZURICH, June 25 (Reuters) - Shares in Swiss biotech company Basilea fell 8 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.

The company said in a statement it had been told by the U.S. Food and Drug Administration (FDA) that potential regulatory approval of ceftobiprole would require additional phase 3 data.

Basilea said it did not intend to begin new phase 3 trials for the treatment without a partner in the United States.

At 0720 GMT shares in Basilea were trading down 8.3 percent at 105.80 Swiss francs. (Reporting by Joshua Franklin)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below